Mark Timney Purdue from Youtube

Ex-Pur­due CEO stands to earn a huge wind­fall in No­var­tis' buy­out of the Med­i­cines Co

Mark Tim­ney, the ex-Pur­due Phar­ma CEO named in dozens of law­suits against the Oxy­Con­tin mak­er, stands to earn over $85 mil­lion in No­var­tis’s $9.7 bil­lion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA